From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines

/in , /by

A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]

Read more

HRS-4357, a Novel PSMA-targeted Radiologand Therapy Phase 3 Trial

/in , , /by

HRS-4357, a novel PSMA-targeted radiopharmaceutical, is poised to enter a landmark Phase III clinical trial targeting metastatic castration-resistant prostate cancer (mCRPC). The trial, received approval from China’s National Medical Products Administration on December 23, 2025, and plans to enroll 370 patients across multiple centers in China. This randomized, open-label, controlled study will directly compare HRS-4357 […]

Read more

Dapagliflozin and Next-Generation Hormonal Agents: Targeting Metabolic Resistance in Metastatic Castrate-Resistant Prostate Cancer

/in , , /by

A new phase 2 clinical trial is now underway to test whether adding dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, to next-generation hormonal agents (darolutamide, abiraterone, apalutamide, enzalutamide) can extend survival in metastatic castrate-resistant prostate cancer. The rationale rests on a fundamental paradox in prostate cancer biology: while early tumors rely on oxidative metabolism and androgen signaling, […]

Read more

CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future

/in , /by

A new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters […]

Read more

Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer

/in , /by

Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. ​ The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]

Read more

Immunotherapy’s Hidden Power: Reprogramming Cancer Back to Normal

/in , /by

In a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]

Read more

Phase 1 Trial of Allogeneic CAR-NK Therapy for Metastatic Prostate Cancer

/in , , /by

A new clinical trial is exploring allogeneic CAR-NK cell therapy targeting PSMA for patients with metastatic castration-resistant prostate cancer, or mCRPC. This exploratory study (not yet recruiting as of late 2025), aims to assess the safety profile alongside early signs of efficacy in men whose disease has progressed despite hormone suppression and other therapies. Unlike […]

Read more

Super-Adjuvant Nanoparticles: Revolutionizing Platform Cancer Vaccination

/in , /by

Super-adjuvant nanoparticles are a new type of cancer vaccine that works much better than older versions. Scientists at the University of Massachusetts Amherst created them. Their main study came out in October 2025 in Cell Reports Medicine. These tiny particles fight cancer by waking up the body’s immune system in a smart way. They mix […]

Read more